

RULES FOR PARTICIPATION 2023 - VALORIZATION SUPPORT CALL

1. ABOUT XARTEC SALUT

Xartec Salut (Xarxa de Tecnologies de la Salut) is a project led and managed by CREB UPC that is made up of 81 research groups from Catalonia that belong to 23 different institutions (universities, hospitals and technology centres). It aims to be a catalyst for R&D&I in the field of Health Technologies in Catalonia, promoting the exchange of knowledge and the transfer of technology between research groups, institutions, hospitals and companies.

2. SCOPE OF THE PROGRAM

Valorization of a technology helps to maximize the value of R&D activities through the different stages of development. It is a critical step for successful technology transfer for many reasons: enhancing the value of the asset in the market, de-risking the development, determining whether the asset has technology transfer potential or not, allowing researchers to have decision windows based on results and facts, increasing the capturing value potential of the research group and the institution, providing real insights for project planification, among others.

Therefore, it is a critical and decisive step where counting with expert support in the field as early as possible can make the difference. However, research groups and institutions often cannot afford to get expert advice to develop their valorization strategies and that may reduce the transferability and the impact of the assets developed.

Hence, in order to provide support to Xartec Salut's research groups and institutions and encourage them to develop adequate valorization strategies, Xartec Salut is launching a new call to support Valorization strategic studies: the **2023 VALORIZATION SUPPORT CALL**.

The Valorization Support Call launched by Xartec Salut is looking for the most promising HealthTech projects to accompany in their way to developing their valorization strategies.

3. ELIGIBLE VALORIZATION STUDIES

Xartec Salut will provide valorization related **strategic studies** developed by specialized experts in the biomedical field. The valorization strategies of scientific results are necessary to make research profitable and market-oriented, to increase the value of these results in order to facilitate its transfer to the productive sector effectively.

Within this call we understand “Valorization strategies” broadly as the creation of economic and social impact from knowledge and scientific capabilities. The valorization function would imply, therefore, all actions necessary to ensure that research results contribute to economic and social development in the most efficient way.

Some of the studies covered within this Call are:

- Valorization strategic plans
- Technology transfer route analysis
- Market access plans
- Market analysis
- Regulatory roadmaps
- Assessment of research results: definition of proof of concept (PoC)
- Other studies that require expert advice in order to build the valorization strategy

Is important to remark that there are **explicitly excluded** activities and costs related to Intellectual property, spin-off creation processes, technological development and any others that are not linked to valorization support studies.

4. APPLICATION PROCESS

The call for applications will be open from **05/09/2023** to **19/09/2023** at 17:00.

Applications will be conducted through the duly submission of the form provided to xartec.salut.creb@upc.edu. Applications that do not include the required information will not be considered eligible. However, it is not expected that the projects already count with extensive documentation at this point, and limited estimations or draft information may be included in the [form](#).

The application form should contain the following information:

- Strategic study required and impact in the project
- Description of the asset & Innovation
- Stage of the development of the asset

- Ownership of the asset(s)
- Current IP strategy
- Current Valorization strategy
- Potential market and competitive advantages

Applications must be submitted in **English**. Incomplete applications or those submitted after the deadline will not be accepted. However, Xartec Salut reserves the right to extend the deadline, communicating this change appropriately to the groups' representatives.

5. EVALUATION & SELECTION PROCESS

Evaluation process will be composed of two sequential stages starting as soon as the application process closes:

- **Stage 1: Verification of eligibility (20/09/2023 - 22/09/2023)**

Every project must comply with all the eligibility criteria described under the following section.

If some critical information is missing due to administrative or human error, Xartec Salut will contact the representative of the project in order to correct the information that would have to be provided before 26/09/2023.

- **Stage 2: Assessment of the applications (27/09/2023 - 02/10/2023)**

Xartec Salut is looking to support early stage project with assets in which the influence of developing their valorization strategy may be critical to their success. Xartec Salut is also taking into account innovation and potential impact that the projects may have in the market whenever transferred.

Thus, the evaluation criteria & weights followed by Xartec Salut in order to assess each of the proposals are set below:

- **50%** Need for developing the Valorization related study
- **25%** Market potential & competitive advantages of the technology
- **25%** Innovation & novelty

The evaluation process will be conducted with the support of specialists in the field.

- **Stage 3: Communication of the selected projects (02/10/2023)**

Xartec Salut will communicate the selected projects on **02/10/2023** via e-mail to the candidates and results will be published in the webpage.

The budget for Xartec Salut's 2023 VALORIZATION SUPPORT CALL is up to **30.000€**.

The strategic studies will be allocated to the best assessed projects until the established budget is covered. We encourage you to conduct the application correctly and submit all the information you have as we expect to be a competitive call.

Those projects that are not selected will have the chance to apply again on future Calls.

6. ELIGIBILITY

Xartec Salut's **2023 VALORIZATION SUPPORT CALL** is available for assets owned or co-owned by members of Xartec Salut network.

The assets presented must meet the following criteria:

1. The **assets** developed must have their application in the **Health field**.
2. The head of the research group or the principal investigator that is the representative at Xartec Salut **must authorize** the presentation of the asset to this call.
3. There is no limit to the number of assets that can be presented by the research group. However, **only one study** can be financed within this call per research group.

7. CONFIDENTIALITY

All the information shared by the research groups in the framework of this call for projects will be treated as confidential information to what is stated at the Agreement signed by the entities pertaining to Xartec salut ("Acord de Xarxa").